Harbor Capital Advisors Inc. Has $194,000 Stock Holdings in Emergent Biosolutions Inc. $EBS

Harbor Capital Advisors Inc. lowered its position in Emergent Biosolutions Inc. (NYSE:EBS) by 17.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,442 shares of the biopharmaceutical company’s stock after selling 6,462 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.06% of Emergent Biosolutions worth $194,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Millennium Management LLC lifted its position in shares of Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Emergent Biosolutions by 313.5% during the 1st quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company’s stock worth $4,048,000 after purchasing an additional 631,794 shares during the last quarter. Prescott Group Capital Management L.L.C. lifted its position in shares of Emergent Biosolutions by 198.9% during the 1st quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock worth $3,050,000 after purchasing an additional 417,671 shares during the last quarter. Palisade Capital Management LP lifted its position in shares of Emergent Biosolutions by 21.6% during the 1st quarter. Palisade Capital Management LP now owns 1,141,589 shares of the biopharmaceutical company’s stock worth $5,548,000 after purchasing an additional 202,857 shares during the last quarter. Finally, Man Group plc acquired a new position in shares of Emergent Biosolutions during the 4th quarter worth about $1,690,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

EBS has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 3rd. Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $13.50.

Emergent Biosolutions Stock Up 3.8%

NYSE:EBS opened at $8.24 on Friday. Emergent Biosolutions Inc. has a 12-month low of $4.02 and a 12-month high of $12.73. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $439.60 million, a P/E ratio of 3.36 and a beta of 2.04. The stock’s fifty day simple moving average is $7.79 and its 200-day simple moving average is $6.48.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.42. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%.The business had revenue of $140.90 million for the quarter, compared to analyst estimates of $148.55 million. Equities research analysts expect that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Insider Buying and Selling at Emergent Biosolutions

In other news, Director Donald W. Degolyer sold 7,844 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the sale, the director owned 137,659 shares of the company’s stock, valued at $1,190,750.35. This trade represents a 5.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kathryn C. Zoon sold 7,086 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the sale, the director directly owned 71,799 shares in the company, valued at approximately $636,857.13. This represents a 8.98% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.